Showing results (361-370 of 432) with videos related to
Sort By:
Pageof 44
AIDS (London, England)|October 6, 2018
Variation in antiretroviral treatment coverage and virological suppression among three HIV key populationsKamilla Grønborg Laut, Leah Shepherd, Magnus Gottfredsson, et al.AIDS (London, England)|June 19, 2018
Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antiviralsLars Peters, Kamilla Laut, Chiara Resnati, et al.Neurology(R) Neuroimmunology & Neuroinflammation|June 21, 2022
Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia GravisDavid Reyes-Leiva, Joaquín López-Contreras, Esther Moga, et al.Iscience|May 30, 2023
Adipose tissue plasticity in pheochromocytoma patients suggests a role of the splicing machinery in human adipose browningMoisés Castellá, Albert Blasco-Roset, Marion Peyrou, et al.Current HIV Research|October 16, 2012
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive studyDaniel Podzamczer, Esteban Martínez, Pere Domingo, et al.HIV Medicine|March 29, 2023
Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohortJorge Palacio-Vieira, Sergio Moreno-Fornés, Yesika Díaz, et al.The Lancet. Infectious Diseases|June 12, 2015
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trialJosé R Arribas, Pierre-Marie Girard, Roland Landman, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialFederico Pulido, Esteban Ribera, María Lagarde, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 StudyHernando Knobel, José M Miró, Beatriz Mahillo, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 20, 2020
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European StudySarah Amele, Lars Peters, Alison Rodger, et al.Pageof 44